Global Retirement Partners LLC Has $364,000 Holdings in Sanofi (NASDAQ:SNY)

Global Retirement Partners LLC grew its holdings in Sanofi (NASDAQ:SNY) by 15.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,315 shares of the company’s stock after purchasing an additional 834 shares during the period. Global Retirement Partners LLC’s holdings in Sanofi were worth $364,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Mezzasalma Advisors LLC increased its holdings in shares of Sanofi by 3.0% in the 3rd quarter. Mezzasalma Advisors LLC now owns 10,234 shares of the company’s stock valued at $590,000 after purchasing an additional 294 shares during the period. Probity Advisors Inc. increased its holdings in shares of Sanofi by 4.9% in the 3rd quarter. Probity Advisors Inc. now owns 14,413 shares of the company’s stock valued at $831,000 after purchasing an additional 671 shares during the period. Leisure Capital Management increased its holdings in shares of Sanofi by 6.0% in the 3rd quarter. Leisure Capital Management now owns 17,870 shares of the company’s stock valued at $1,030,000 after purchasing an additional 1,010 shares during the period. Stillwater Capital Advisors LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at about $208,000. Finally, Opal Wealth Advisors LLC increased its holdings in Sanofi by 11.7% in the third quarter. Opal Wealth Advisors LLC now owns 5,127 shares of the company’s stock worth $295,000 after buying an additional 538 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Down 2.3 %

SNY opened at $53.66 on Tuesday. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $136.16 billion, a price-to-earnings ratio of 29.16, a P/E/G ratio of 1.57 and a beta of 0.60. The business has a 50 day moving average of $56.13 and a 200-day moving average of $51.62.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the prior year, the business earned $0.95 earnings per share. Sanofi’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sanofi will post 4.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.